Clinical Trial Update: Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating bevacizumab, erlotinib, and FOLFOX in patients with untreated metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)
• FOLFOX regimen (folinic acid (leucovorin) + fluorouracil + oxaliplatin)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Colorectal Cancer, Neoplasm Metastasis | Phase 2 | Status: COMPLETED